Literature DB >> 12479086

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.

Michael Bauer1, Peter C Whybrow, Jules Angst, Marcio Versiani, Hans-Jürgen Möller.   

Abstract

These practice guidelines for the biological treatment of unipolar depressive disorders were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal for developing these guidelines was to systematically review all available evidence pertaining to the treatment of unipolar depressive disorders, and to produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating patients with these conditions. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for depressive disorders, as well as from meta-analyses and reviews on the efficacy of antidepressant medications and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and was then categorized into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of unipolar depressive disorders, as well as the management of the acute and continuation-phase treatment. These guidelines are primarily concerned with the biological treatment (including antidepressants, other psychopharmacological and hormonal medications, electroconvulsive therapy, light therapy, adjunctive and novel therapeutic strategies) of young adults and also, albeit to a lesser extent, children, adolescents and older adults.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12479086     DOI: 10.3109/15622970209150599

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  67 in total

Review 1.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

2.  Socio-economic inequalities in first-time use of antidepressants: a population-based study.

Authors:  D G Hansen; J Søndergaard; W Vach; L F Gram; J U Rosholm; P B Mortensen; J Kragstrup
Journal:  Eur J Clin Pharmacol       Date:  2004-02-17       Impact factor: 2.953

3.  How close is evidence to truth in evidence-based treatment of mental disorders?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-22       Impact factor: 5.270

4.  [Efficiency of antidepressant therapy for patients with less severe depression].

Authors:  T C Baghai; H J Möller; S Nitschmann
Journal:  Internist (Berl)       Date:  2010-11       Impact factor: 0.743

5.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

6.  The future of antidepressant pharmacotherapy.

Authors:  David Baldwin; Chris Thompson
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

Review 7.  [Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making].

Authors:  H-J Möller; W Maier
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

8.  Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.

Authors:  Julia Kirchheiner; Cristina Rodriguez-Antona
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder.

Authors:  Christopher Baethge; Philipp Gruschka; Michael N Smolka; Anne Berghöfer; Tom Bschor; Bruno Müller-Oerlinghausen; Michael Bauer
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

Review 10.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.